# Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

> **NCT07226557** · — · ACTIVE_NOT_RECRUITING · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 5000 (estimated)

## Conditions studied

- Carbapenem Resistant Bacterial Infection
- Acinetobacter Baumannii Infection
- Antimicrobial Drug Resistance

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07226557
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226557, "Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07226557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*